Healthcare News Acetazolamide Market | Page 2

REPORT DESCRIPTION
Acetazolamide Market – Overview
The global acetazolamide market size was valued at US$ 183.2 Mn in 2017, and is expected to witness a
CAGR of 4.8% during the forecast period (2018 – 2026).
Acetazolamide is carbonic anhydrase inhibitor, used in adjuvant treatment of chronic simple (open-angle)
glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma, epilepsy, edema due
to congestive heart failure, drug-induced edema, and acute mountain sickness in climbers. Acetazolamide
promotes acclimatization to altitude, increases bicarbonate secretion by the kidneys, induces metabolic
acidosis, and stimulates ventilation. Furthermore, according to the BMJ Journal, September 2012,
acetazolamide in doses of 250 mg, 500 mg, and 750 mg daily are more effective compared to placebo for
preventing acute mountain sickness. In addition, acetazolamide 250 mg daily is the lowest effective dose to
prevent acute mountain sickness.
© Coherent market Insights. All Rights Reserved